查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1715479

製藥連續製造市場（按組件、技術類型、配方、最終用戶、治療領域和應用）—2025-2030 年全球預測

Pharmaceutical Continuous Manufacturing Market by Component, Technology Type, Formulations, End-user, Therapeutic Area, Applications - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 184 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計 2023 年製藥連續生產市場價值將達到 15.8 億美元，2024 年將成長至 17.6 億美元，到 2030 年將達到 35.1 億美元，複合年成長率為 12.08%。

主要市場統計數據
基準年2023年 15.8億美元
預計2024年 17.6億美元
預測年份 2030 35.1億美元
複合年成長率（%） 12.08%

在當今充滿活力的製藥環境中，連續製造的出現正在重塑傳統模式。這種創新方法將尖端的自動化流程、先進的控制和精簡的操作結合在一起，開創了生產效率和品質的新時代。隨著全球製藥業面臨產品設計和監管要求日益複雜的情況，連續生產因其提供毫不妥協的一致性和即時製程監控而脫穎而出。

組織正在逐漸將重點從批次轉移到連續操作，以實現更大的擴充性、縮短生產時間和資源最佳化。製造實踐的演變不僅受到市場需求的驅動，也受到對強大、靈活和有彈性的供應鏈的需求的驅動。在此背景下，確保品質合規性同時維持高生產吞吐量是連續製造有效解決的平衡行為。

尖端數位解決方案與傳統生產方法的結合創造了一個創新與可靠性相結合的肥沃平台。透過投資這種變革性方法，公司不僅可以降低營運成本，還可以為改善流程分析和永續製造實踐打開大門。在全球市場中，持續製造的承諾不僅限於業務效率；它代表了醫藥產品概念化、開發和交付方式的模式轉移。

重新定義製藥業格局的轉型

在技​​術、法規和市場需求融合的推動下，製藥業正在經歷重大轉型。從傳統批量生產向連續生產的轉變不僅僅是操作上的升級；這是一場從根本上改變公司設計和執行生產策略方式的革命。

該行業的關鍵轉變包括更加重視提高流程可靠性、智慧技術整合以及即時監控和自適應控制系統。隨著世界各地的監管機構越來越重視品質源自於設計 (QbD) 和流程分析技術 (PAT)，連續製造流程完美地融入了這個前瞻性框架。結果是，對品質問題的反應更加靈活，對需求波動的反應更加適應，並且對流程檢驗和改進的方法更加創新。

市場領導者正在利用這些變化，充分利用連續製造的潛力來創建能夠提供一致的產品品質、更短的生產週期和降低的營運風險的製造環境。這種結構轉型是由對卓越的不懈追求所驅動的，持續改進和技術整合是每個決策的核心。公司不僅在實現生產線現代化，而且還在重塑整個供應鏈以滿足不斷變化的市場需求。

數位創新與既定生產通訊協定的融合正在成為變革的催化劑，為各行業的效率、敏捷性和彈性設定新的基準。這種轉變並不局限於單一領域，而是滲透到業務、法規和市場策略中，為製藥製造業創造更具競爭力和永續性的未來。

不斷發展的市場提供了關鍵的細分洞察

細緻地了解市場區隔對於駕馭連續製造領域至關重要。細分分析從各個方面揭示市場，每個維度都為生產創新和業務成功的市場促進因素提供了寶貴的見解。基於組件的研究強調了設備、服務以及軟體和控制解決方案的多種方法。在此框架內，設備研究進一步分為攪拌機、進料機、製粒機和反應器等特定領域，確保製造商瞄準無縫生產流程所需的最關鍵設備。

我們對技術類型的關注引入了另一層差異：分離整合連續和半連續製造系統。這種區別至關重要，因為它反映了頻譜技術成熟度和適應特定操作要求的能力。同時，透過劑型分析（液體、半固態和固態）為製造商提供了全面的視角，以評估各種產品類型的連續生產流程的適用性和靈活性。

根據最終用戶活動對市場進行細分進一步深化了這項洞察，使我們能夠區分契約製造組織和製藥公司。每個部分都有自己的要求和性能基準，圍繞著品質、擴充性和成本效益進行對話。此外，透過考慮循環系統疾病、中樞神經系統疾病、感染疾病、代謝疾病和腫瘤等治療領域，細分更加深入，展示了產品特異性如何推動製造業創新。

最後，仔細研究原料藥、生物製藥和口服藥物等應用，凸顯了將製造技術與產品的最終用途和市場需求結合的重要性。這些細分見解不僅突顯了連續製造的多面性，而且有助於指南日益複雜的市場環境中的策略決策。

目錄

第1章 引言

第2章調查方法

第3章執行摘要

第4章 市場概述

第5章 市場洞察

  • 市場動態
    • 驅動程式
      • 全球慢性病盛行率不斷上升
      • 對高效率、可靠的藥品生產系統的需求日益增加
      • 鼓勵製藥業採用連續生產方式的監管支持和獎勵
    • 限制因素
      • 啟動成本高，且缺乏經過適當訓練的專業人員
    • 機會
      • 製造技術的進步實現了即時數據監控和流程最佳化
      • 傳統製造技術開發的投資和資金激增
    • 任務
      • 傳統製造程序的技術限制和複雜性
  • 市場區隔分析
    • 組件：製藥連續生產的效率－用於連續製藥生產的軟體和控制解決方案
    • 技術類型：利用整合連續生產系統實現高品質產品並節省時間和成本
    • 配方：藥物輸送系統的個人化正在增加固態劑型的使用。
    • 最終用戶：製藥公司採用此方法可提高生產效率和控制力。
    • 治療領域：增加感染疾病的使用以提高製藥生產的靈活性和產能
    • 用途：擴大口服藥物的使用，以提高藥物配方的一致性和品質
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 經濟
    • 社會
    • 技術的
    • 合法的
    • 環境

6. 藥品連續生產市場（依組件）

  • 裝置
    • 混合器
    • 進紙器
    • 製粒機
    • 核子反應爐
  • 服務
  • 軟體和控制解決方案

7. 醫藥連續製造市場（依技術類型）

  • 整合連續生產系統
  • 半連續生產系統

8. 藥品連續生產市場（依配方）

  • 液體製劑
  • 半固態製劑
  • 固態製劑

第9章。醫藥連續製造市場（按最終用戶）

  • 契約製造組織
  • 製藥公司

第 10 章 藥品連續製造市場（依治療領域）

  • 心血管疾病
  • 中樞神經系統疾病
  • 感染疾病
  • 代謝紊亂
  • 腫瘤學

第 11 章 醫藥連續製造市場（依應用）

  • 活性藥物成分
  • 生物製藥
  • 口服藥物

12.美洲藥品連續製造市場

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美國

13. 亞太地區製藥連續生產市場

  • 澳洲
  • 中國
  • 印度
  • 印尼
  • 日本
  • 馬來西亞
  • 菲律賓
  • 新加坡
  • 韓國
  • 台灣
  • 泰國
  • 越南

14.歐洲、中東和非洲製藥連續生產市場

  • 丹麥
  • 埃及
  • 芬蘭
  • 法國
  • 德國
  • 以色列
  • 義大利
  • 荷蘭
  • 奈及利亞
  • 挪威
  • 波蘭
  • 卡達
  • 俄羅斯
  • 沙烏地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公國
  • 英國

第15章競爭格局

  • 2023年市場佔有率分析
  • 2023年FPNV定位矩陣
  • 競爭情境分析
  • 戰略分析與建議

公司名單

  • ABB Ltd
  • Amazon Web Services, Inc.
  • Capgemini SE
  • Chemtrix BV by AGI Group
  • Continuus Pharmaceuticals
  • Coperion GmbH
  • Corning Incorporated
  • Emerson Electric Co.
  • Fette Compacting
  • GEA Group AG
  • Gebruder Lodige Maschinenbau GmbH
  • Glatt GmbH
  • Honeywell International, Inc.
  • Hosokawa Micron Corporation
  • IMA Group
  • Korsch AG
  • LB Bohle Maschinen und Verfahren GmbH
  • Pall Corporation by Danaher Corporation
  • Repligen Corporation
  • Rockwell Automation Inc.
  • Scott Equipment Company
  • Siemens AG
  • Syntegon Technology GmbH
  • Thermo Fisher Scientific Inc.
Product Code: MRR-030EE48515D8

The Pharmaceutical Continuous Manufacturing Market was valued at USD 1.58 billion in 2023 and is projected to grow to USD 1.76 billion in 2024, with a CAGR of 12.08%, reaching USD 3.51 billion by 2030.

KEY MARKET STATISTICS
Base Year [2023] USD 1.58 billion
Estimated Year [2024] USD 1.76 billion
Forecast Year [2030] USD 3.51 billion
CAGR (%) 12.08%

In today's dynamic pharmaceutical environment, the emergence of continuous manufacturing is reshaping traditional paradigms. This innovative approach integrates state-of-the-art automated processes, advanced controls, and streamlined operations to usher in a new era of production efficiency and quality. As the global pharmaceutical industry confronts increasing complexity in product design and regulatory expectations, continuous manufacturing stands out by providing uncompromised consistency and real-time process monitoring.

Organizations are progressively shifting their focus from batch processing to continuous operations to achieve enhanced scalability, reduced production times, and better resource optimization. The evolution in manufacturing practices is not merely a response to market demand-it is also driven by the need for a robust, agile, and resilient supply chain. In this landscape, ensuring quality compliance while maintaining high production throughput is a balancing act that continuous manufacturing addresses effectively.

The integration of cutting-edge digital solutions with traditional production methodologies has created a fertile platform where innovation meets reliability. As companies invest in this transformative methodology, they not only stand to reduce operational costs but also open doors to improved process analytics and sustainable manufacturing practices. In a well-connected global market, the promise of continuous manufacturing extends beyond operational efficiency; it represents a paradigm shift in how pharmaceutical products are conceptualized, developed, and delivered.

Transformative Shifts Redefining the Pharmaceutical Landscape

The pharmaceutical industry is experiencing a monumental shift driven by the convergence of technology, regulation, and market demands. The transformation from traditional batch production methods to continuous manufacturing represents more than an operational upgrade; it is a revolution that is fundamentally altering the way companies design and execute their production strategies.

Key shifts in the industry include the drive for increased process reliability, the integration of smart technologies, and an enhanced focus on real-time monitoring and adaptive control systems. As regulatory bodies around the world increasingly emphasize quality by design (QbD) and process analytical technology (PAT), the continuous manufacturing process is aligning perfectly with this forward-thinking framework. The result is an industry that is more nimble in responding to quality issues, more adaptive in managing fluctuations in demand, and more innovative in its approach to process validation and improvement.

Market leaders are capitalizing on these changes by embracing the full potential of continuous manufacturing, thereby creating manufacturing environments that offer consistent product quality, reduced production cycle times, and lower operational risks. This structural transformation is propelled by the relentless pursuit of excellence, where continuous improvements and technology integration are at the heart of every decision. Companies are not only modernizing their production lines but also reinventing their entire supply chain to meet the demands of an ever-changing marketplace.

The fusion of digital innovation with established production protocols serves as a catalyst for change, setting new benchmarks for efficiency, agility, and resilience across the industry. This shift is not confined to any single segment-it permeates across operations, regulation, and market strategy, forging a more competitive and sustainable future for pharmaceutical manufacturing.

Key Segmentation Insights from an Evolving Marketplace

A nuanced understanding of market segmentation is essential for navigating the continuous manufacturing terrain. The segmentation analysis unpacks the market along various dimensions, each offering valuable insights into the drivers of production innovation and operational success. An examination based on components reveals a diversified approach that spans equipment, services, and software & control solutions. In this framework, equipment studies are further divided into specifics such as blenders, feeders, granulators, and reactors, ensuring that manufacturers target the most critical instruments necessary for seamless production flow.

A focus on technology types introduces another layer of differentiation, separating integrated continuous manufacturing systems from semi-continuous manufacturing systems. This distinction is pivotal, as it reflects the spectrum of technological maturity and the capability to adapt to specific operational requirements. Meanwhile, analysis according to formulations-encompassing liquid, semi-solid, and solid forms-provides a comprehensive lens through which manufacturers assess the suitability and flexibility of continuous processes for various product types.

Delineating the market by end-user activities further enhances this insight, distinguishing between contract manufacturing organizations and pharmaceutical companies. Each segment brings its own set of requirements and performance benchmarks, shaping the dialogue on quality, scalability, and cost-effectiveness. The segmentation is deepened through an examination of therapeutic areas, such as cardiovascular diseases, central nervous system disorders, infectious diseases, metabolic disorders, and oncology, illustrating how product specificity drives manufacturing innovation.

Finally, a detailed look at applications, including active pharmaceutical ingredients, biologics, and oral drugs, underscores the importance of aligning manufacturing technologies with product end-use and market demands. Together, these segmentation insights not only highlight the multiple facets of continuous manufacturing but also serve to guide strategic decision-making in an increasingly complex market landscape.

Based on Component, market is studied across Equipment, Services, and Software & Control Solutions. The Equipment is further studied across Blenders, Feeders, Granulators, and Reactors.

Based on Technology Type, market is studied across Integrated Continuous Manufacturing Systems and Semi-Continuous Manufacturing Systems.

Based on Formulations, market is studied across Liquid Formulations, Semi-solid Formulations, and Solid Formulations.

Based on End-user, market is studied across Contract Manufacturing Organizations and Pharmaceutical Companies.

Based on Therapeutic Area, market is studied across Cardiovascular Diseases, Central Nervous System Disorders, Infectious Diseases, Metabolic Disorders, and Oncology.

Based on Applications, market is studied across Active Pharmaceutical Ingredients, Biologics, and Oral Drugs.

Regional Trends and Insights Driving Global Change

The continuous manufacturing revolution is unfolding within a globally interconnected framework where regional dynamics play a critical role in shaping industry trends and policy directions. In the Americas, the focus has been on leveraging advanced technologies to streamline production processes and improve quality assurance. This region is characterized by a strong emphasis on regulatory compliance and innovation-driven growth, ensuring that pharmaceutical companies are well-equipped to meet both domestic and international quality standards.

Across Europe, the Middle East, and Africa, there is a prevailing synergy between tradition and technology, with legacy systems gradually giving way to more integrated, digitally enhanced production lines. In these regions, investment in infrastructure and research is propelling companies toward embracing continuous manufacturing processes with a strong commitment to sustainability and operational efficiency. The proactive governmental policies and regulatory frameworks have created an environment where innovation is not only encouraged but is viewed as essential for competitive survival.

The Asia-Pacific region, meanwhile, stands out as a dynamic hub of rapid industrial growth and technology adoption. Market players in this fast-evolving region are increasingly embracing continuous manufacturing as a means to meet surging demand and expand their capabilities in both domestic and international markets. Enhanced focus on research and development, coupled with robust economic expansion, has facilitated an environment ripe for the integration of continuous manufacturing practices.

Each region brings its unique strengths and challenges to the table, offering a rich tapestry of opportunities for those prepared to adapt to evolving market conditions. The interplay between technological advancement, regulatory support, and market demand across these regions accentuates the global trajectory towards an industry that values innovation, consistency, and operational excellence.

Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

Evaluating Industry Leaders and Key Company Contributions

A myriad of influential companies has emerged at the forefront of continuous manufacturing, each contributing a distinct set of capabilities and innovations that are propelling the industry forward. Titans such as ABB Ltd, Amazon Web Services, Inc., and Capgemini SE have been instrumental in integrating sophisticated automation and digital solutions into the manufacturing landscape. Their contributions have enabled precision control and real-time data analytics, thereby ensuring that operational processes remain agile and secure.

Companies like Chemtrix BV by AGI Group and Continuus Pharmaceuticals have harnessed deep sector expertise to tailor their solutions to the unique demands of pharmaceutical production, focusing on efficient process design and robust scale-up mechanisms. In parallel, organizations such as Coperion GmbH and Corning Incorporated are recognized for their innovative engineering that supports the seamless integration of equipment and process optimization. Their advanced solutions improve overall production efficiency through meticulous design and long-term reliability.

Industry veterans like Emerson Electric Co. and Fette Compacting have further bolstered the market by offering robust hardware and integrated systems that ensure high-quality performance across diverse manufacturing environments. GEA Group AG and Gebruder Lodige Maschinenbau GmbH are notable for their significant investments in research and technological development, continuously pushing the envelope in design refinement and operational excellence. The specialized expertise provided by entities such as Glatt GmbH, Honeywell International, Inc., and Hosokawa Micron Corporation has catalyzed innovation in the pharmaceutical production line through bespoke control and automation systems.

Leaders like IMA Group, Korsch AG, L.B. Bohle Maschinen und Verfahren GmbH, and Pall Corporation by Danaher Corporation are widely acknowledged for their strategic contributions in advancing process reliability and efficiency. Companies including Repligen Corporation, Rockwell Automation Inc., and Scott Equipment Company have further demonstrated a deep commitment to quality leadership through their robust process solutions. Siemens AG, Syntegon Technology GmbH, and Thermo Fisher Scientific Inc. round out the list, showcasing the diverse blend of technical expertise and forward-thinking strategies that define the competitive edge in the continuous manufacturing space.

Collectively, these key players not only solidify the foundation of technological advancement in pharmaceutical manufacturing but also inspire ongoing innovation and investment in an industry poised for continued transformation.

The report delves into recent significant developments in the Pharmaceutical Continuous Manufacturing Market, highlighting leading vendors and their innovative profiles. These include ABB Ltd, Amazon Web Services, Inc., Capgemini SE, Chemtrix BV by AGI Group, Continuus Pharmaceuticals, Coperion GmbH, Corning Incorporated, Emerson Electric Co., Fette Compacting, GEA Group AG, Gebruder Lodige Maschinenbau GmbH, Glatt GmbH, Honeywell International, Inc., Hosokawa Micron Corporation, IMA Group, Korsch AG, L.B. Bohle Maschinen und Verfahren GmbH, Pall Corporation by Danaher Corporation, Repligen Corporation, Rockwell Automation Inc., Scott Equipment Company, Siemens AG, Syntegon Technology GmbH, and Thermo Fisher Scientific Inc.. Actionable Recommendations to Drive Industry Transformation

In light of the transformative innovations and dynamic market trends, industry leaders need to adopt targeted strategies to sustain competitive advantage and drive continuous improvement. One of the primary recommendations is to take an integrated approach toward technology deployment. Emphasizing the importance of setting up a robust digital infrastructure that integrates automated equipment with advanced control solutions is critical. Leaders must prioritize upfront investments in scalable technologies that ease future expansions while maintaining operational reliability.

Companies should also focus on process standardization and robust quality controls as they transition from batch to continuous manufacturing. Establishing a framework for continuous process monitoring and real-time data analytics will not only mitigate risks but also enable the proactive identification of potential inefficiencies. This approach calls for the convergence of operational technology and information technology in a manner that supports data-driven decision-making.

Considering market segmentation insights, it is essential to align technology choices with specific operational needs. Whether transitioning to integrated or semi-continuous systems, organizations should choose technologies that best match the product formulations and end-user requirements they serve. The assessment should encompass everything from the specific production equipment-blenders, feeders, granulators, and reactors-to the service and software layers that complement them.

In a rapidly evolving regulatory environment, investing in compliance and adaptability is an imperative. Regular review and adjustment of quality management systems, aligned with emerging global standards, will fortify operational resilience. Regional considerations also warrant strategic attention; companies should cultivate operational hubs that mirror regional strengths, be it the technological rigor of the Americas, the balanced regulatory support in Europe, Middle East and Africa, or the aggressive growth dynamics in Asia-Pacific.

Furthermore, fostering strategic collaborations with leading technology providers and process experts can propel operational excellence and innovation. Partnerships not only grant access to cutting-edge solutions and market insights but also provide a platform for shared risk management and development. This multidimensional approach-driven by investments in technology, process standardization, and strategic alliances-will enable industry leaders to navigate market fluctuations effectively and secure their role in the future of pharmaceutical manufacturing.

Conclusion: Embracing a Future of Continuous Innovation

The journey toward continuous manufacturing is emblematic of a broader shift in the pharmaceutical industry toward efficiency, innovation, and resilience. By harnessing state-of-the-art technologies and embracing digital integration, the industry is breaking free from traditional constraints and setting new benchmarks in product quality and operational agility.

This evolution is driven by a confluence of factors including evolving regulatory landscapes, technological advancements, and market pressures that demand faster and more reliable production processes. As organizations invest in training, infrastructure, and research and development, the benefits of continuous manufacturing become increasingly tangible through reduced production costs, enhanced product consistency, and a robust capacity for innovation.

Moreover, the emergence of varied market segmentation insights ensures that players at every level-from equipment operators and process engineers to strategic decision-makers-are better informed about where to focus their efforts. The collective industry shift, supported by consistent technological breakthroughs and market-driven adaptations, heralds a new era where collaborative innovation and operational excellence reign supreme.

Ultimately, the insights and trends discussed here illustrate that continuous manufacturing is not just a temporary innovation; it is a foundational shift that will continue to influence the landscape of pharmaceutical production for years to come. Leaders who embrace this change are poised to create agile, efficient, and future-ready manufacturing observatories that redefine global healthcare manufacturing.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Increasing prevalence of chronic diseases worldwide
      • 5.1.1.2. Growing need for efficient and reliable pharmaceutical production systems
      • 5.1.1.3. Regulatory support and incentives facilitating the adoption of continuous manufacturing in pharmaceutical industry
    • 5.1.2. Restraints
      • 5.1.2.1. High initial costs and scarcity of adequately trained professionals
    • 5.1.3. Opportunities
      • 5.1.3.1. Advancements in manufacturing technologies enabling real-time data monitoring and process optimization
      • 5.1.3.2. Surging investments and funding for the development of continuous manufacturing technology
    • 5.1.4. Challenges
      • 5.1.4.1. Technological limitations and complexity of continuous manufacturing processes
  • 5.2. Market Segmentation Analysis
    • 5.2.1. Component: Efficiency in pharmaceutical continuous manufacturing of software & control solutions for continuous drug production
    • 5.2.2. Technology Type: Utilization of integrated continuous manufacturing systems due to high-quality products and reducing time and cost
    • 5.2.3. Formulations: Increasing usage of solid formulations due to personalization in drug delivery systems.
    • 5.2.4. End-user: Adoption of pharmaceutical companies to enhance production efficiency and control.
    • 5.2.5. Therapeutic Area: Rising usage of infectious diseases for enhancing agility and capacity in pharmaceutical production
    • 5.2.6. Applications: Expanding use of oral drugs for consistency and quality in drug formulation
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Pharmaceutical Continuous Manufacturing Market, by Component

  • 6.1. Introduction
  • 6.2. Equipment
    • 6.2.1. Blenders
    • 6.2.2. Feeders
    • 6.2.3. Granulators
    • 6.2.4. Reactors
  • 6.3. Services
  • 6.4. Software & Control Solutions

7. Pharmaceutical Continuous Manufacturing Market, by Technology Type

  • 7.1. Introduction
  • 7.2. Integrated Continuous Manufacturing Systems
  • 7.3. Semi-Continuous Manufacturing Systems

8. Pharmaceutical Continuous Manufacturing Market, by Formulations

  • 8.1. Introduction
  • 8.2. Liquid Formulations
  • 8.3. Semi-solid Formulations
  • 8.4. Solid Formulations

9. Pharmaceutical Continuous Manufacturing Market, by End-user

  • 9.1. Introduction
  • 9.2. Contract Manufacturing Organizations
  • 9.3. Pharmaceutical Companies

10. Pharmaceutical Continuous Manufacturing Market, by Therapeutic Area

  • 10.1. Introduction
  • 10.2. Cardiovascular Diseases
  • 10.3. Central Nervous System Disorders
  • 10.4. Infectious Diseases
  • 10.5. Metabolic Disorders
  • 10.6. Oncology

11. Pharmaceutical Continuous Manufacturing Market, by Applications

  • 11.1. Introduction
  • 11.2. Active Pharmaceutical Ingredients
  • 11.3. Biologics
  • 11.4. Oral Drugs

12. Americas Pharmaceutical Continuous Manufacturing Market

  • 12.1. Introduction
  • 12.2. Argentina
  • 12.3. Brazil
  • 12.4. Canada
  • 12.5. Mexico
  • 12.6. United States

13. Asia-Pacific Pharmaceutical Continuous Manufacturing Market

  • 13.1. Introduction
  • 13.2. Australia
  • 13.3. China
  • 13.4. India
  • 13.5. Indonesia
  • 13.6. Japan
  • 13.7. Malaysia
  • 13.8. Philippines
  • 13.9. Singapore
  • 13.10. South Korea
  • 13.11. Taiwan
  • 13.12. Thailand
  • 13.13. Vietnam

14. Europe, Middle East & Africa Pharmaceutical Continuous Manufacturing Market

  • 14.1. Introduction
  • 14.2. Denmark
  • 14.3. Egypt
  • 14.4. Finland
  • 14.5. France
  • 14.6. Germany
  • 14.7. Israel
  • 14.8. Italy
  • 14.9. Netherlands
  • 14.10. Nigeria
  • 14.11. Norway
  • 14.12. Poland
  • 14.13. Qatar
  • 14.14. Russia
  • 14.15. Saudi Arabia
  • 14.16. South Africa
  • 14.17. Spain
  • 14.18. Sweden
  • 14.19. Switzerland
  • 14.20. Turkey
  • 14.21. United Arab Emirates
  • 14.22. United Kingdom

15. Competitive Landscape

  • 15.1. Market Share Analysis, 2023
  • 15.2. FPNV Positioning Matrix, 2023
  • 15.3. Competitive Scenario Analysis
    • 15.3.1. STEERLife and Callidus partner to enhance global drug development
    • 15.3.2. Enzene launch EnzeneX 2.0 platform for enhanced biologics manufacturing at CPHI milan 2024
    • 15.3.3. Syntegon launch modular bioprocessing platform to streamline biopharmaceutical manufacturing
    • 15.3.4. Eli Lilly invests USD 1.8 billion in Irish manufacturing to advance pharmaceutical production
    • 15.3.5. Hovione and GEA partner to innovate continuous tableting technology
    • 15.3.6. Sartorius and Repligen launch integrated bioreactor system for enhanced biopharmaceutical production
    • 15.3.7. Sandoz partners with Just - Evotec biologics to expand biosimilar pipeline
    • 15.3.8. Arranta Bio sign contract with MIT to enhance continuous manufacturing of mRNA therapeutics
    • 15.3.9. Curia and Corning collaborate to innovate biopharmaceutical continuous flow manufacturing
    • 15.3.10. WuXi STA launch continuous manufacturing line for oral solid drugs in China
  • 15.4. Strategy Analysis & Recommendation
    • 15.4.1. Syntegon Technology GmbH
    • 15.4.2. Siemens AG
    • 15.4.3. Chemtrix BV
    • 15.4.4. Emerson Electric Co.

Companies Mentioned

  • 1. ABB Ltd
  • 2. Amazon Web Services, Inc.
  • 3. Capgemini SE
  • 4. Chemtrix BV by AGI Group
  • 5. Continuus Pharmaceuticals
  • 6. Coperion GmbH
  • 7. Corning Incorporated
  • 8. Emerson Electric Co.
  • 9. Fette Compacting
  • 10. GEA Group AG
  • 11. Gebruder Lodige Maschinenbau GmbH
  • 12. Glatt GmbH
  • 13. Honeywell International, Inc.
  • 14. Hosokawa Micron Corporation
  • 15. IMA Group
  • 16. Korsch AG
  • 17. L.B. Bohle Maschinen und Verfahren GmbH
  • 18. Pall Corporation by Danaher Corporation
  • 19. Repligen Corporation
  • 20. Rockwell Automation Inc.
  • 21. Scott Equipment Company
  • 22. Siemens AG
  • 23. Syntegon Technology GmbH
  • 24. Thermo Fisher Scientific Inc.

LIST OF FIGURES

  • FIGURE 1. PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET MULTI-CURRENCY
  • FIGURE 2. PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET MULTI-LANGUAGE
  • FIGURE 3. PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET RESEARCH PROCESS
  • FIGURE 4. PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET SIZE, 2023 VS 2030
  • FIGURE 5. GLOBAL PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 6. GLOBAL PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 7. GLOBAL PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET SIZE, BY COMPONENT, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET SIZE, BY COMPONENT, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET SIZE, BY TECHNOLOGY TYPE, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET SIZE, BY TECHNOLOGY TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. GLOBAL PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET SIZE, BY FORMULATIONS, 2023 VS 2030 (%)
  • FIGURE 13. GLOBAL PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET SIZE, BY FORMULATIONS, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. GLOBAL PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET SIZE, BY END-USER, 2023 VS 2030 (%)
  • FIGURE 15. GLOBAL PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET SIZE, BY END-USER, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. GLOBAL PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET SIZE, BY THERAPEUTIC AREA, 2023 VS 2030 (%)
  • FIGURE 17. GLOBAL PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET SIZE, BY THERAPEUTIC AREA, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. GLOBAL PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET SIZE, BY APPLICATIONS, 2023 VS 2030 (%)
  • FIGURE 19. GLOBAL PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET SIZE, BY APPLICATIONS, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. AMERICAS PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 21. AMERICAS PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 22. UNITED STATES PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 23. UNITED STATES PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 24. ASIA-PACIFIC PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 25. ASIA-PACIFIC PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 26. EUROPE, MIDDLE EAST & AFRICA PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 27. EUROPE, MIDDLE EAST & AFRICA PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 28. PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 29. PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET DYNAMICS
  • TABLE 7. GLOBAL PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET SIZE, BY EQUIPMENT, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET SIZE, BY BLENDERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET SIZE, BY FEEDERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET SIZE, BY GRANULATORS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET SIZE, BY REACTORS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET SIZE, BY EQUIPMENT, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET SIZE, BY SERVICES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET SIZE, BY SOFTWARE & CONTROL SOLUTIONS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET SIZE, BY INTEGRATED CONTINUOUS MANUFACTURING SYSTEMS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET SIZE, BY SEMI-CONTINUOUS MANUFACTURING SYSTEMS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET SIZE, BY FORMULATIONS, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET SIZE, BY LIQUID FORMULATIONS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET SIZE, BY SEMI-SOLID FORMULATIONS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 22. GLOBAL PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET SIZE, BY SOLID FORMULATIONS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 23. GLOBAL PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 24. GLOBAL PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET SIZE, BY CONTRACT MANUFACTURING ORGANIZATIONS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 25. GLOBAL PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET SIZE, BY PHARMACEUTICAL COMPANIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 26. GLOBAL PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 27. GLOBAL PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET SIZE, BY CARDIOVASCULAR DISEASES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 28. GLOBAL PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET SIZE, BY CENTRAL NERVOUS SYSTEM DISORDERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 29. GLOBAL PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET SIZE, BY INFECTIOUS DISEASES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 30. GLOBAL PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET SIZE, BY METABOLIC DISORDERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 31. GLOBAL PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET SIZE, BY ONCOLOGY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 32. GLOBAL PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET SIZE, BY APPLICATIONS, 2018-2030 (USD MILLION)
  • TABLE 33. GLOBAL PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET SIZE, BY ACTIVE PHARMACEUTICAL INGREDIENTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 34. GLOBAL PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET SIZE, BY BIOLOGICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 35. GLOBAL PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET SIZE, BY ORAL DRUGS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 36. AMERICAS PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 37. AMERICAS PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET SIZE, BY EQUIPMENT, 2018-2030 (USD MILLION)
  • TABLE 38. AMERICAS PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2030 (USD MILLION)
  • TABLE 39. AMERICAS PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET SIZE, BY FORMULATIONS, 2018-2030 (USD MILLION)
  • TABLE 40. AMERICAS PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 41. AMERICAS PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 42. AMERICAS PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET SIZE, BY APPLICATIONS, 2018-2030 (USD MILLION)
  • TABLE 43. AMERICAS PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 44. ARGENTINA PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 45. ARGENTINA PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET SIZE, BY EQUIPMENT, 2018-2030 (USD MILLION)
  • TABLE 46. ARGENTINA PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2030 (USD MILLION)
  • TABLE 47. ARGENTINA PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET SIZE, BY FORMULATIONS, 2018-2030 (USD MILLION)
  • TABLE 48. ARGENTINA PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 49. ARGENTINA PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 50. ARGENTINA PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET SIZE, BY APPLICATIONS, 2018-2030 (USD MILLION)
  • TABLE 51. BRAZIL PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 52. BRAZIL PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET SIZE, BY EQUIPMENT, 2018-2030 (USD MILLION)
  • TABLE 53. BRAZIL PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2030 (USD MILLION)
  • TABLE 54. BRAZIL PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET SIZE, BY FORMULATIONS, 2018-2030 (USD MILLION)
  • TABLE 55. BRAZIL PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 56. BRAZIL PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 57. BRAZIL PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET SIZE, BY APPLICATIONS, 2018-2030 (USD MILLION)
  • TABLE 58. CANADA PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 59. CANADA PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET SIZE, BY EQUIPMENT, 2018-2030 (USD MILLION)
  • TABLE 60. CANADA PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2030 (USD MILLION)
  • TABLE 61. CANADA PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET SIZE, BY FORMULATIONS, 2018-2030 (USD MILLION)
  • TABLE 62. CANADA PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 63. CANADA PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 64. CANADA PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET SIZE, BY APPLICATIONS, 2018-2030 (USD MILLION)
  • TABLE 65. MEXICO PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 66. MEXICO PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET SIZE, BY EQUIPMENT, 2018-2030 (USD MILLION)
  • TABLE 67. MEXICO PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2030 (USD MILLION)
  • TABLE 68. MEXICO PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET SIZE, BY FORMULATIONS, 2018-2030 (USD MILLION)
  • TABLE 69. MEXICO PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 70. MEXICO PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 71. MEXICO PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET SIZE, BY APPLICATIONS, 2018-2030 (USD MILLION)
  • TABLE 72. UNITED STATES PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 73. UNITED STATES PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET SIZE, BY EQUIPMENT, 2018-2030 (USD MILLION)
  • TABLE 74. UNITED STATES PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2030 (USD MILLION)
  • TABLE 75. UNITED STATES PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET SIZE, BY FORMULATIONS, 2018-2030 (USD MILLION)
  • TABLE 76. UNITED STATES PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 77. UNITED STATES PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 78. UNITED STATES PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET SIZE, BY APPLICATIONS, 2018-2030 (USD MILLION)
  • TABLE 79. UNITED STATES PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 80. ASIA-PACIFIC PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 81. ASIA-PACIFIC PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET SIZE, BY EQUIPMENT, 2018-2030 (USD MILLION)
  • TABLE 82. ASIA-PACIFIC PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2030 (USD MILLION)
  • TABLE 83. ASIA-PACIFIC PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET SIZE, BY FORMULATIONS, 2018-2030 (USD MILLION)
  • TABLE 84. ASIA-PACIFIC PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 85. ASIA-PACIFIC PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 86. ASIA-PACIFIC PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET SIZE, BY APPLICATIONS, 2018-2030 (USD MILLION)
  • TABLE 87. ASIA-PACIFIC PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 88. AUSTRALIA PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 89. AUSTRALIA PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET SIZE, BY EQUIPMENT, 2018-2030 (USD MILLION)
  • TABLE 90. AUSTRALIA PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2030 (USD MILLION)
  • TABLE 91. AUSTRALIA PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET SIZE, BY FORMULATIONS, 2018-2030 (USD MILLION)
  • TABLE 92. AUSTRALIA PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 93. AUSTRALIA PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 94. AUSTRALIA PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET SIZE, BY APPLICATIONS, 2018-2030 (USD MILLION)
  • TABLE 95. CHINA PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 96. CHINA PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET SIZE, BY EQUIPMENT, 2018-2030 (USD MILLION)
  • TABLE 97. CHINA PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2030 (USD MILLION)
  • TABLE 98. CHINA PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET SIZE, BY FORMULATIONS, 2018-2030 (USD MILLION)
  • TABLE 99. CHINA PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 100. CHINA PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 101. CHINA PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET SIZE, BY APPLICATIONS, 2018-2030 (USD MILLION)
  • TABLE 102. INDIA PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 103. INDIA PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET SIZE, BY EQUIPMENT, 2018-2030 (USD MILLION)
  • TABLE 104. INDIA PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2030 (USD MILLION)
  • TABLE 105. INDIA PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET SIZE, BY FORMULATIONS, 2018-2030 (USD MILLION)
  • TABLE 106. INDIA PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 107. INDIA PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 108. INDIA PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET SIZE, BY APPLICATIONS, 2018-2030 (USD MILLION)
  • TABLE 109. INDONESIA PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 110. INDONESIA PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET SIZE, BY EQUIPMENT, 2018-2030 (USD MILLION)
  • TABLE 111. INDONESIA PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2030 (USD MILLION)
  • TABLE 112. INDONESIA PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET SIZE, BY FORMULATIONS, 2018-2030 (USD MILLION)
  • TABLE 113. INDONESIA PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 114. INDONESIA PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 115. INDONESIA PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET SIZE, BY APPLICATIONS, 2018-2030 (USD MILLION)
  • TABLE 116. JAPAN PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 117. JAPAN PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET SIZE, BY EQUIPMENT, 2018-2030 (USD MILLION)
  • TABLE 118. JAPAN PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2030 (USD MILLION)
  • TABLE 119. JAPAN PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET SIZE, BY FORMULATIONS, 2018-2030 (USD MILLION)
  • TABLE 120. JAPAN PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 121. JAPAN PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 122. JAPAN PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET SIZE, BY APPLICATIONS, 2018-2030 (USD MILLION)
  • TABLE 123. MALAYSIA PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 124. MALAYSIA PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET SIZE, BY EQUIPMENT, 2018-2030 (USD MILLION)
  • TABLE 125. MALAYSIA PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2030 (USD MILLION)
  • TABLE 126. MALAYSIA PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET SIZE, BY FORMULATIONS, 2018-2030 (USD MILLION)
  • TABLE 127. MALAYSIA PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 128. MALAYSIA PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 129. MALAYSIA PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET SIZE, BY APPLICATIONS, 2018-2030 (USD MILLION)
  • TABLE 130. PHILIPPINES PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 131. PHILIPPINES PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET SIZE, BY EQUIPMENT, 2018-2030 (USD MILLION)
  • TABLE 132. PHILIPPINES PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2030 (USD MILLION)
  • TABLE 133. PHILIPPINES PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET SIZE, BY FORMULATIONS, 2018-2030 (USD MILLION)
  • TABLE 134. PHILIPPINES PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 135. PHILIPPINES PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 136. PHILIPPINES PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET SIZE, BY APPLICATIONS, 2018-2030 (USD MILLION)
  • TABLE 137. SINGAPORE PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 138. SINGAPORE PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET SIZE, BY EQUIPMENT, 2018-2030 (USD MILLION)
  • TABLE 139. SINGAPORE PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2030 (USD MILLION)
  • TABLE 140. SINGAPORE PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET SIZE, BY FORMULATIONS, 2018-2030 (USD MILLION)
  • TABLE 141. SINGAPORE PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 142. SINGAPORE PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 143. SINGAPORE PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET SIZE, BY APPLICATIONS, 2018-2030 (USD MILLION)
  • TABLE 144. SOUTH KOREA PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 145. SOUTH KOREA PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET SIZE, BY EQUIPMENT, 2018-2030 (USD MILLION)
  • TABLE 146. SOUTH KOREA PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2030 (USD MILLION)
  • TABLE 147. SOUTH KOREA PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET SIZE, BY FORMULATIONS, 2018-2030 (USD MILLION)
  • TABLE 148. SOUTH KOREA PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 149. SOUTH KOREA PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 150. SOUTH KOREA PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET SIZE, BY APPLICATIONS, 2018-2030 (USD MILLION)
  • TABLE 151. TAIWAN PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 152. TAIWAN PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET SIZE, BY EQUIPMENT, 2018-2030 (USD MILLION)
  • TABLE 153. TAIWAN PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2030 (USD MILLION)
  • TABLE 154. TAIWAN PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET SIZE, BY FORMULATIONS, 2018-2030 (USD MILLION)
  • TABLE 155. TAIWAN PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 156. TAIWAN PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 157. TAIWAN PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET SIZE, BY APPLICATIONS, 2018-2030 (USD MILLION)
  • TABLE 158. THAILAND PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 159. THAILAND PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET SIZE, BY EQUIPMENT, 2018-2030 (USD MILLION)
  • TABLE 160. THAILAND PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2030 (USD MILLION)
  • TABLE 161. THAILAND PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET SIZE, BY FORMULATIONS, 2018-2030 (USD MILLION)
  • TABLE 162. THAILAND PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 163. THAILAND PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 164. THAILAND PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET SIZE, BY APPLICATIONS, 2018-2030 (USD MILLION)
  • TABLE 165. VIETNAM PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 166. VIETNAM PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET SIZE, BY EQUIPMENT, 2018-2030 (USD MILLION)
  • TABLE 167. VIETNAM PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2030 (USD MILLION)
  • TABLE 168. VIETNAM PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET SIZE, BY FORMULATIONS, 2018-2030 (USD MILLION)
  • TABLE 169. VIETNAM PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 170. VIETNAM PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 171. VIETNAM PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET SIZE, BY APPLICATIONS, 2018-2030 (USD MILLION)
  • TABLE 172. EUROPE, MIDDLE EAST & AFRICA PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 173. EUROPE, MIDDLE EAST & AFRICA PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET SIZE, BY EQUIPMENT, 2018-2030 (USD MILLION)
  • TABLE 174. EUROPE, MIDDLE EAST & AFRICA PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2030 (USD MILLION)
  • TABLE 175. EUROPE, MIDDLE EAST & AFRICA PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET SIZE, BY FORMULATIONS, 2018-2030 (USD MILLION)
  • TABLE 176. EUROPE, MIDDLE EAST & AFRICA PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 177. EUROPE, MIDDLE EAST & AFRICA PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 178. EUROPE, MIDDLE EAST & AFRICA PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET SIZE, BY APPLICATIONS, 2018-2030 (USD MILLION)
  • TABLE 179. EUROPE, MIDDLE EAST & AFRICA PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 180. DENMARK PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 181. DENMARK PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET SIZE, BY EQUIPMENT, 2018-2030 (USD MILLION)
  • TABLE 182. DENMARK PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2030 (USD MILLION)
  • TABLE 183. DENMARK PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET SIZE, BY FORMULATIONS, 2018-2030 (USD MILLION)
  • TABLE 184. DENMARK PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 185. DENMARK PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 186. DENMARK PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET SIZE, BY APPLICATIONS, 2018-2030 (USD MILLION)
  • TABLE 187. EGYPT PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 188. EGYPT PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET SIZE, BY EQUIPMENT, 2018-2030 (USD MILLION)
  • TABLE 189. EGYPT PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2030 (USD MILLION)
  • TABLE 190. EGYPT PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET SIZE, BY FORMULATIONS, 2018-2030 (USD MILLION)
  • TABLE 191. EGYPT PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 192. EGYPT PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 193. EGYPT PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET SIZE, BY APPLICATIONS, 2018-2030 (USD MILLION)
  • TABLE 194. FINLAND PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 195. FINLAND PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET SIZE, BY EQUIPMENT, 2018-2030 (USD MILLION)
  • TABLE 196. FINLAND PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2030 (USD MILLION)
  • TABLE 197. FINLAND PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET SIZE, BY FORMULATIONS, 2018-2030 (USD MILLION)
  • TABLE 198. FINLAND PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 199. FINLAND PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 200. FINLAND PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET SIZE, BY APPLICATIONS, 2018-2030 (USD MILLION)
  • TABLE 201. FRANCE PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 202. FRANCE PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET SIZE, BY EQUIPMENT, 2018-2030 (USD MILLION)
  • TABLE 203. FRANCE PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2030 (USD MILLION)
  • TABLE 204. FRANCE PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET SIZE, BY FORMULATIONS, 2018-2030 (USD MILLION)
  • TABLE 205. FRANCE PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 206. FRANCE PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 207. FRANCE PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET SIZE, BY APPLICATIONS, 2018-2030 (USD MILLION)
  • TABLE 208. GERMANY PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 209. GERMANY PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET SIZE, BY EQUIPMENT, 2018-2030 (USD MILLION)
  • TABLE 210. GERMANY PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2030 (USD MILLION)
  • TABLE 211. GERMANY PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET SIZE, BY FORMULATIONS, 2018-2030 (USD MILLION)
  • TABLE 212. GERMANY PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 213. GERMANY PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 214. GERMANY PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET SIZE, BY APPLICATIONS, 2018-2030 (USD MILLION)
  • TABLE 215. ISRAEL PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 216. ISRAEL PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET SIZE, BY EQUIPMENT, 2018-2030 (USD MILLION)
  • TABLE 217. ISRAEL PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2030 (USD MILLION)
  • TABLE 218. ISRAEL PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET SIZE, BY FORMULATIONS, 2018-2030 (USD MILLION)
  • TABLE 219. ISRAEL PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 220. ISRAEL PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 221. ISRAEL PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET SIZE, BY APPLICATIONS, 2018-2030 (USD MILLION)
  • TABLE 222. ITALY PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 223. ITALY PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET SIZE, BY EQUIPMENT, 2018-2030 (USD MILLION)
  • TABLE 224. ITALY PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2030 (USD MILLION)
  • TABLE 225. ITALY PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET SIZE, BY FORMULATIONS, 2018-2030 (USD MILLION)
  • TABLE 226. ITALY PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 227. ITALY PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 228. ITALY PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET SIZE, BY APPLICATIONS, 2018-2030 (USD MILLION)
  • TABLE 229. NETHERLANDS PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 230. NETHERLANDS PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET SIZE, BY EQUIPMENT, 2018-2030 (USD MILLION)
  • TABLE 231. NETHERLANDS PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2030 (USD MILLION)
  • TABLE 232. NETHERLANDS PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET SIZE, BY FORMULATIONS, 2018-2030 (USD MILLION)
  • TABLE 233. NETHERLANDS PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 234. NETHERLANDS PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 235. NETHERLANDS PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET SIZE, BY APPLICATIONS, 2018-2030 (USD MILLION)
  • TABLE 236. NIGERIA PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 237. NIGERIA PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET SIZE, BY EQUIPMENT, 2018-2030 (USD MILLION)
  • TABLE 238. NIGERIA PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2030 (USD MILLION)
  • TABLE 239. NIGERIA PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET SIZE, BY FORMULATIONS, 2018-2030 (USD MILLION)
  • TABLE 240. NIGERIA PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 241. NIGERIA PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 242. NIGERIA PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET SIZE, BY APPLICATIONS, 2018-2030 (USD MILLION)
  • TABLE 243. NORWAY PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 244. NORWAY PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET SIZE, BY EQUIPMENT, 2018-2030 (USD MILLION)
  • TABLE 245. NORWAY PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2030 (USD MILLION)
  • TABLE 246. NORWAY PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET SIZE, BY FORMULATIONS, 2018-2030 (USD MILLION)
  • TABLE 247. NORWAY PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 248. NORWAY PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 249. NORWAY PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET SIZE, BY APPLICATIONS, 2018-2030 (USD MILLION)
  • TABLE 250. POLAND PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 251. POLAND PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET SIZE, BY EQUIPMENT, 2018-2030 (USD MILLION)
  • TABLE 252. POLAND PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2030 (USD MILLION)
  • TABLE 253. POLAND PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET SIZE, BY FORMULATIONS, 2018-2030 (USD MILLION)
  • TABLE 254. POLAND PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 255. POLAND PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 256. POLAND PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET SIZE, BY APPLICATIONS, 2018-2030 (USD MILLION)
  • TABLE 257. QATAR PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 258. QATAR PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET SIZE, BY EQUIPMENT, 2018-2030 (USD MILLION)
  • TABLE 259. QATAR PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2030 (USD MILLION)
  • TABLE 260. QATAR PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET SIZE, BY FORMULATIONS, 2018-2030 (USD MILLION)
  • TABLE 261. QATAR PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 262. QATAR PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 263. QATAR PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET SIZE, BY APPLICATIONS, 2018-2030 (USD MILLION)
  • TABLE 264. RUSSIA PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 265. RUSSIA PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET SIZE, BY EQUIPMENT, 2018-2030 (USD MILLION)
  • TABLE 266. RUSSIA PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2030 (USD MILLION)
  • TABLE 267. RUSSIA PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET SIZE, BY FORMULATIONS, 2018-2030 (USD MILLION)
  • TABLE 268. RUSSIA PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 269. RUSSIA PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 270. RUSSIA PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET SIZE, BY APPLICATIONS, 2018-2030 (USD MILLION)
  • TABLE 271. SAUDI ARABIA PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 272. SAUDI ARABIA PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET SIZE, BY EQUIPMENT, 2018-2030 (USD MILLION)
  • TABLE 273. SAUDI ARABIA PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2030 (USD MILLION)
  • TABLE 274. SAUDI ARABIA PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET SIZE, BY FORMULATIONS, 2018-2030 (USD MILLION)
  • TABLE 275. SAUDI ARABIA PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 276. SAUDI ARABIA PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 277. SAUDI ARABIA PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET SIZE, BY APPLICATIONS, 2018-2030 (USD MILLION)
  • TABLE 278. SOUTH AFRICA PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 279. SOUTH AFRICA PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET SIZE, BY EQUIPMENT, 2018-2030 (USD MILLION)
  • TABLE 280. SOUTH AFRICA PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2030 (USD MILLION)
  • TABLE 281. SOUTH AFRICA PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET SIZE, BY FORMULATIONS, 2018-2030 (USD MILLION)
  • TABLE 282. SOUTH AFRICA PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 283. SOUTH AFRICA PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 284. SOUTH AFRICA PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET SIZE, BY APPLICATIONS, 2018-2030 (USD MILLION)
  • TABLE 285. SPAIN PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 286. SPAIN PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET SIZE, BY EQUIPMENT, 2018-2030 (USD MILLION)
  • TABLE 287. SPAIN PHARMACEUTICAL CONTINUOUS MANUFACTURING MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2030 (USD MILLION)
  • TABLE 288. SPAIN PHARMA